Alliance for Pandemic Preparedness

March 10, 2021

SARS-COV-2 Antibody Prevalence in Patients on Dialysis in the US in January 2021

Category:

Topic:

Keywords (Tags): ,

  • [Pre-print, not peer-reviewed] A cross-sectional assessment of SARS-CoV-2 seroprevalence among patients in the US receiving dialysis (n = 21,424) in January 2021 with the goal of estimating the seroprevalence in the general US adult population found that seroprevalence was 18.9% in the study sample, which translated to an estimated 18.7% in the US dialysis population, and 21.3% in the US adult population. Patients in the sample were disproportionately older and from minority race/ethnic groups. Younger people (18-44 years), those self-identifying as Hispanic or living in Hispanic neighborhoods, and those living in the poorest neighborhoods were among the subgroups with the highest seroprevalence (25.9%, 25.1%, 24.8%, respectively). Compared to data from July 2020, there was diminished variability in seroprevalence by geographic region and urban-rural status. 

Anand et al. (Mar 9, 2021). SARS-COV-2 Antibody Prevalence in Patients on Dialysis in the US in January 2021. Pre-print downloaded Mar 10 from https://doi.org/10.1101/2021.03.07.21252786